LGND - Ligand Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LGND is currently covered by 6 analysts with an average price target of $149.97. This is a potential upside of $18.39 (13.98%) from yesterday's end of day stock price of $131.58.

Ligand Pharmaceuticals's activity chart (see below) currently has 126 price targets and 106 ratings on display. The stock rating distribution of LGND is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 83.49% with an average time for these price targets to be met of 318.58 days.

Highest price target for LGND is $160, Lowest price target is $135, average price target is $145.

Most recent stock forecast was given by ROBERT WASSERMAN from BENCHMARK on 23-Dec-2024. First documented stock forecast 12-Feb-2014.

Currently out of the existing stock ratings of LGND, 29 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$135

$3.42 (2.60%)

$135

7 months 10 days ago
(23-Dec-2024)

9/9 (100%)

$21.2 (18.63%)

215

Buy

$160

$28.42 (21.60%)

$150

7 months 17 days ago
(16-Dec-2024)

13/15 (86.67%)

$37.66 (30.78%)

549

Buy

$157

7 months 22 days ago
(11-Dec-2024)

22/40 (55%)

$35.75 (29.48%)

461

Buy

$143

$11.42 (8.68%)

$140

7 months 22 days ago
(11-Dec-2024)

4/5 (80%)

$22.64 (18.81%)

322

Buy

$147

$15.42 (11.72%)

$135

8 months 25 days ago
(08-Nov-2024)

1/2 (50%)

$25.75 (21.24%)

287

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LGND (Ligand Pharmaceuticals) average time for price targets to be met?

On average it took 318.58 days on average for the stock forecasts to be realized with a an average price target met ratio 83.49

Which analyst has the current highest performing score on LGND (Ligand Pharmaceuticals) with a proven track record?

SCOTT HENRY

Which analyst has the most public recommendations on LGND (Ligand Pharmaceuticals)?

Scott Henry works at ALLIANCE GLOBAL PARTNERS and has 7 price targets and 4 ratings on LGND

Which analyst is the currently most bullish on LGND (Ligand Pharmaceuticals)?

Balaji Prasad with highest potential upside - $28.42

Which analyst is the currently most reserved on LGND (Ligand Pharmaceuticals)?

Esther Rajavelu with lowest potential downside - -$66.08

Ligand Pharmaceuticals in the News

Orchestra BioMed secures $70 million from Ligand and Medtronic

NEW HOPE, Pa. – Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced Thursday it has secured $70 million in new capital from Ligand Pharmaceuticals (NASDAQ:LGND) and Medtronic (NYSE:MDT) to advance its late-stage partnered cardiology programs. Ligand, which maintains a strong financial health score according to InvestingPro analysis, has seen its stock rise over 26% year-to-date, demonstrating robust...

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?